Skip to main content
Retour
Watch Compare

OS Therapies Inc

Qualité des données : 83%
OSTX
NYSE Manufacturing Chemicals
1,34 €
▲ 0,09 € (6,80%)
Cap. Boursière: 54,02 M
Prix
1,34 €
Cap. Boursière
54,02 M
Fourchette du Jour
1,23 € — 1,35 €
Fourchette 52 Semaines
1,12 € — 2,57 €
Volume
1 156 591
Ouverture 1,25 €
Moyenne 50J / 200J
1,40 €
4,34% below
Moyenne 50J / 200J
1,74 €
23,09% below

Quick Summary

Points Clés

Debt/Equity of 0,03 — conservative balance sheet
Negative free cash flow of -14,24 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-670,19%
En dessous de la moyenne du secteur (-53,47%)
ROIC-382,41%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,03
En dessous de la moyenne du secteur (0,31)
Current Ratio0,56
Interest Coverage-13,99

Valorisation

PE (TTM)
-1,88
En dessous de la moyenne du secteur (-1,47)
P/B Ratio14,85
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,9 -1,5
P/B 14,9 1,6
ROE % -670,2 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,0 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -28,75 M
ROE -670,19% ROA -298,53%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,24 M
ROIC -382,41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,03 Current Ratio 0,56
Interest Coverage -13,99 Asset Turnover N/A
Working Capital -1,82 M Tangible Book Value -3,23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,88 Forward P/E N/A
P/B Ratio 14,85 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -26,36%
Market Cap 54,02 M Enterprise Value 54,12 M
Per Share
EPS (Diluted TTM) -0,98 Revenue / Share N/A
FCF / Share -0,35 OCF / Share -0,35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 49,52%
SBC-Adj. FCF -16,90 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -28,75 M -8,88 M
EPS (Diluted) -0,98 -0,88
Gross Profit — —
Operating Income -28,71 M -6,81 M
EBITDA — —
R&D Expenses 16,36 M 2,84 M
SG&A Expenses — —
D&A 363 085,0 —
Interest Expense 2,05 M 2,05 M
Income Tax — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 6,84 M 5,54 M
Total Liabilities 11,86 M 4,73 M
Shareholders' Equity -6,10 M -5,24 M
Total Debt 100 000,0 100 000,0
Cash & Equivalents — —
Current Assets 332 912,0 5,53 M
Current Liabilities 11,76 M 4,63 M